



Suppl. Fig S4

A



B



Supplemental Figure S4. T β R-I antagonism at low dose in combination with gemcitabine does not alter vascularization of pancreatic tumors. **A.** Quantifications of mean vascular area (% CD31+ area; left) and mean vascular density (number of CD31+ vessels per μm^2) are shown for indicated treatment groups. $N \geq 4$ tumors per group, treatment administered for 14 days. **B.** Representative examples of employed gating for identification of major immune cell populations to profile immune landscape of KP16 tumors. For PD-L1+ and cleaved caspase 3+ CD45-CK19+ cancer cell fractions, histograms are shown on the right.